Patent classifications
Y
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Load children
Y10
TECHNICAL SUBJECTS COVERED BY FORMER USPC
Load children
Y10S
TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Load children
530/00
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Load children Filter patents View analytics View as hierarchy Open in page

Y10S530/86

Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
10870693 · 2020-12-22 · ·

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WTIH A DLL4 ANTAGONIST AND AN ANTI-HYPERTENSIVE AGENT
20180346556 · 2018-12-06 · ·

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
09982042 · 2018-05-29 · ·

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent
20170166632 · 2017-06-15 · ·

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.